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Summary
Background and objectives Because little is known about long-term treatment-related nephrotoxicity, the aim
was to determine risk factors for renal impairment long after childhood cancer treatment.
Design, setting, participants, & measurements Data from 763 adult childhood cancer survivors (414 men) were
obtained during regular visits at the late-effects clinic between 2003 and 2009. Median follow-up time was 18.3
years (range=5.0–58.2). Glomerular function was assessed by estimated GFR (using the Modification of Diet in
Renal Disease formula), urinary albumin creatinine ratio, and tubular function by urinary b2-microglobulin
creatinine ratio. The association with treatment factors was analyzedwith covariance analysis for estimated GFR
and logistic regression for urinary albumin and urinary b2-microglobulin creatinine ratios.
Results Survivors treated with nephrectomy and abdominal irradiation had significantly lower estimated GFR
than survivors not treated with nephrectomy/abdominal irradiation (estimated mean=90 ml/min per 1.73 m2
versus 106, P,0.001). Estimated GFR was significantly lower in survivors after treatment with high-dose
ifosfamide (88 versus 98, P=0.02) and high-dose cisplatin (83 versus 101, P=0.004) compared with survivors
not treated with these regimen. Nephrectomy combined with abdominal radiotherapy (odds ratio=3.14, 95%
confidence interval=1.02; 9.69) and high-dose cisplatin (odds ratio=5.19, 95% confidence interval=1.21; 22.21)
was associated with albuminuria. High-dose ifosfamide (odds ratio=6.19, 95% confidence interval=2.45; 15.67)
was associated with increased urinary b2-microglobulin creatinine ratio. Hypertension was present in 23.4% of
survivors and 31.4% of renal tumor survivors.
Conclusions Treatment with unilateral nephrectomy, abdominal radiotherapy, cisplatin, and ifosfamide was
associated with lower estimated GFR. Persisting tubular damage was related to ifosfamide treatment.
Clin J Am Soc Nephrol 8: ccc–ccc, 2013. doi: 10.2215/CJN.09980912
Introduction
Childhood cancer survival rates have improved sub-
stantially over the last decades, leading to a 5-year
survival of 80% (1). To date, 1 of 570 young adults is a
childhood cancer survivor (2). However, even a long
time after cessation of treatment, mortality rates seem
to be significantly higher than in the general popula-
tion (3). Not only excess of mortality but also excess
of morbidity, including second malignancies, endo-
crinopathies, and cardiovascular disease, are impor-
tant issues (4). Impaired renal function is one of the
known potential late-effects after childhood cancer
treatment at either the glomerular or tubular level.
Nephrotoxic chemotherapy, abdominal irradiation,
and nephrectomy contribute to renal injury (5). Neph-
rotoxicity induced by chemotherapeutic drugs, in-
cluding ifosfamide, cisplatin and carboplatin, can
manifest as acute reversible renal failure at the glo-
meruli or proximal tubules (6–10). Cyclophospha-
mide, an isomer of ifosfamide, is not thought to
cause nephrotoxicity, possibly because of different
pharmacology, but clinical studies to confirm,
especially at very long-term follow-up, are lacking.
In general, AKI during childhood cancer treatment
remains subclinical and reversible but may lead to
CKD later in life. To date, studies on nephrotoxicity
in large cohorts of childhood cancer survivors at
long-term (.5 years) and very long-term (.20 years)
follow-up are limited. Studies so far mainly focus on
single therapies and short-term follow-up (6,7,9,10).
Because reduced GFR and albuminuria are indepen-
dent predictors of cardiovascular disease and all-
cause mortality, studies focusing on long-term renal
function to define risk groups, implement early inter-
ventions, and limit potentially nephrotoxic treat-
ments are needed (11–16). In the present study, we
determined risk factors for renal impairment many
years after childhood cancer treatment.
Materials and Methods
Ethics Statement
The data described in the current retrospective
study were obtained during regular visits at the
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assessed using the standard guidelines for screening late
effects after childhood cancer using Good Clinical Practice.
An official written informed consent from every patient
that visited the outpatient clinic was obtained according to
standards of the Institutional Review Board.
Subjects
We performed a retrospective cross-sectional single-
center study. Follow-up at the late-effects outpatient clinic
for long-term childhood cancer survivors starts 5 years
after cessation of treatment and is individualized based on
cancer diagnosis, treatment protocol, and current clinical
condition. Patients younger than 18 years or without serum
creatinine data available were excluded.
Data Collection
Data concerning disease and treatment protocol were
retrieved from our local database and completed from the
medical records. Follow-up time was defined as time since
cessation of treatment until most recent renal function
measurement. Follow-up data included height, weight, BP,
glomerular function defined as estimated GFR (eGFR),
glomerular damage defined as albuminuria, and tubular
injury defined as elevated b2-microglobulinuria. BP was
electronically measured and defined as hypertensive if
systolic BP was $140 mmHg, diastolic BP was $90
mmHg, or any antihypertensive medication was used
(17). Body mass index (BMI) was calculated as weight in
kilograms divided by the squared height in meters.
Laboratory Measurements
Serum creatinine, assessed using the Roche enzymatic
assay, urinary creatinine, urinary b2-microglobulin, and
urinary albumin were analyzed in a fully automated
computerized laboratory system with a Hitachi 917
chemistry analyzer (Roche Diagnostics, Almere, The
Netherlands).
Evaluation of Renal Function
Serum creatinine (Cr) concentration was used to calcu-
late the eGFR by using the abbreviated Modification of
Diet in Renal Disease equation (18–20). Kidney disease
was categorized according to the Kidney Disease Out-
comes Quality Initiative guidelines: stage 3 eGFR=30–59
ml/min per 1.73 m2, stage 4 eGFR=15–29 ml/min per
1.73 m2, and stage 5 eGFR,15 ml/min per 1.73 m2 with
or without renal replacement therapy (19). Age-specific
SD scores were calculated to compare eGFR data with
data from healthy Dutch references retrieved from the
Nijmegen Biomedical study (n=3732, aged 18–85 years)
(21). Urinary albumin creatinine ratio (U-ACR) was cal-
culated to determine the presence of microalbuminuria,
which was defined as U-ACR$3.5 mg/mmol Cr (women)
and $2.5 mg/mmol Cr (men). Macroalbuminuria was
defined as U-ACR.35 mg/mmol Cr (women) and .25
mg/mmol Cr (men) (19,22). Urinary b2-microglobulin
creatinine ratio (U-b2MCR) was measured at the same
time point as U-ACR and expressed in the same units
(normal value,0.04 mg/mmol Cr). If urinary pH,6,
measurements of U-b2MCR were unreliable and excluded
from the analysis.
Statistical Analyses
Statistical analyses were performed with the Statistical
Package for Social Sciences (SPSS 18.0, Chicago, IL). Results
are reported as median (range) for baseline characteristics
and non-normative outcome variables and mean (95%
confidence interval [95% CI]) for SD scores. For univariate
analysis, the one-sample t test was used for SDS, and the
Mann–Whitney U test was used for group comparisons.
The chi-squared test was used for nominal variables. The
associations between eGFR and baseline and treatment
characteristics were analyzed using covariance analysis
and are expressed as adjusted means. The associations be-
tween albuminuria and high U-b2MCR ($0.04 mg/mmol
Cr) and baseline and treatment characteristics were ana-
lyzed with logistic regression and are expressed as odds
ratios (ORs). Models were corrected for age, sex (except for
eGFR), age at diagnosis, and BMI. Dummy variables for
subjects treated with nephrectomy without abdominal ir-
radiation, nephrectomy with abdominal irradiation, and
abdominal irradiation without nephrectomy were added
to the models. Total cumulative dosages of chemothera-
peutics were divided into two groups using the median as
the cutoff limit. Because only 16 survivors had been treated
with carboplatin, this group was analyzed as a whole. For
all chemotherapeutics, the group of survivors not treated
with the subsequent chemotherapy was used as the refer-
ence category. Because the total cumulative dosages of
methotrexate (MTX) were missing for 235 survivors, we
added being treated with MTX as a dichotomous variable.
To assess the influence of hypertension, this variable was




Of 885 adult survivors of childhood cancer diagnosed
and treated between 1964 and 2005, 763 survivors met the
inclusion criteria, of which 85 survivors survived a renal
tumor. One patient was excluded because of bilateral
nephrectomy, and one patient was excluded because of
nephrophtosis before cancer diagnosis. Baseline and treat-
ment characteristics are presented in Tables 1 and 2. Me-
dian follow-up time was 18.3 years (range=5.0–58.2), and
median age was 26.9 years (17.8–65.8). Cisplatin, carbopla-
tin, and/or ifosfamide had been administered in 51 (7%),
16 (2%), and 75 (10%) survivors, respectively. Cyclophos-
phamide and MTX had been administered in 305 (39.9%)
and 319 (41.8%) survivors, respectively. The group of sur-
vivors who had received abdominal radiotherapy (n=47)
consisted mainly of renal tumor survivors (n=29) and neu-
roblastoma survivors (n=8). None of the survivors had re-
ceived renal shielding during abdominal or total body
irradiation. Unilateral nephrectomy was performed in all
85 renal tumor survivors (11.1%) (Table 2). Data of U-ACR
and U-b2MCR were not available in survivors that had
visited the outpatient clinic before 2006 (n=266, 35%). Sur-
vivors with available data were significantly younger than
survivors with missing data (25.9 versus 29.3, P,0.001).
Also, a higher percentage of survivors had been treated
with nephrotoxic chemotherapy (19% versus 9%,
P,0.001). However, the cohort was comparable with
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regard to sex, diagnosis, and treatment with nephrectomy,
abdominal radiotherapy, and total body irradiation.
Glomerular Function
eGFR of the total group was not significantly different
from healthy controls (mean SDS=0.03, 95% CI=20.05;
0.11, P=0.47). An eGFR between 60 and 90 ml/min per
1.73 m2 was found in 241 (31.5%) cases, an eGFR between
30 and 60 ml/min per 1.73 m2 was found in 16 (2.1%)
cases, an eGFR between 15 and 30 ml/min per 1.73 m2 was
found in 2 (0.3%) cases, and an eGFR below 15 ml/min
per 1.73 m2 was found in 3 (0.4%) cases (Table 2). Of the
latter three cases (all renal tumor survivors), two cases
had a functioning renal transplant: one case since child-
hood (cause by Denys Drash syndrome and nephroblasto-
matosis of the contra lateral kidney) and one case was
treated with dialysis since 2009. Prevalence of ESRD was
10 times higher than in the normal Dutch population
(,0.04%) (23). Survivors treated with unilateral nephrectomy
(all 85 renal tumor survivors, SDS=20.59, 95% CI=20.85;
20.33, P,0.001), abdominal radiotherapy (n=47,
SDS=20.42, 95% CI=20.83; 20.01, P=0.04), or the combi-
nation of both (n=29, SDS=20.49, 95% CI=20.98; 20.01,
P=0.05) had significantly lower eGFR compared with
healthy references (Supplemental Table 1). After adjust-
ment for age at diagnosis and BMI, survivors treated
with nephrectomy alone (91 ml/min per 1.73 m2, 95%
CI=76; 106, P,0.001) or combined with abdominal irradi-
ation (90 ml/min per 1.73 m2, 95% CI=74; 106, P,0.001)
had significantly lower eGFR than survivors not treated
with nephrectomy or abdominal radiotherapy (106 ml/min
per 1.73 m2, 95% CI=95; 119) (Table 3). Additionally, eGFR
was significantly lower after treatment with high-dose
ifosfamide (88 ml/min per 1.73 m2, 95% CI=73; 103 versus
98 ml/min per 1.73 m2, 95% CI=85; 112, P=0.02) and high-
dose cisplatin (83 ml/min per 1.73 m2, 95% CI=66; 100
versus 101, 95% CI=89; 113, P=0.004) compared with
survivors who had not been treated with these regimen.
Table 1. Baseline and treatment characteristics of adult childhood cancer survivors
Baseline Characteristics and
Treatment Factors
Total Cohort N (%)/Median
(Range; n=763 [100])
Renal Tumor Survivors N
(%)/Median (Range; n=85 [100])
Sex (men) 414 (54.3) 45 (52.9)
Age at diagnosis (yr) 7.3 (0.0–18.0) 2.8 (0.0–15.0)
Age at follow-up (yr) 26.9 (17.8–65.8) 27.9 (17.9–49.0)
Follow-up time (yr) 18.3 (5.0–58.2) 24.4 (12.2–41.1)
Long-term survivors (.5 yr) 438 (57.4) —
Very long-term survivors (.20 yr) 325 (42.6) —
Diagnosis N (%)
Acute lymphoblastic leukemia/T-NHL 216 (28.3) —
Acute myeloid leukemia 26 (3.4) —
B cell non-Hodgkin’s lymphoma 68 (8.9) —
Hodgkin’s lymphoma 80 (10.5) —
Bone tumor 35 (4.6) —
Renal tumor 85 (11.1) —
Neuroblastoma 50 (6.6) —
Langerhans cell histiocytosis 14 (1.8) —
Germ cell tumor 18 (2.4) —
Malignant mesenchymal tumor 67 (8.8) —
Brain tumor 76 (9.9) —
Other tumors 28 (3.7) —
Recurrence ($1) 91 (11.9) 8 (9)
Treatment N (%) Median (Range) N (%) Median (Range)
Chemotherapy TCD (mg/m2) TCD (mg/m2)
Cisplatin 51 (6.7) 450 (18–900) 1 (1.2) 450
Carboplatin 16 (2.1) 2050 (500–7150) 0 NA
Ifosfamide 75 (9.8) 18,000 (4–96,000) 4 (4.7) 36000 (30,000–36,000)
Cyclophosphamide 305 (40.0) 3500 (45–45,990) 5 (5.9) 5250 (250–7400)
Methotrexate 319 (41.8) 1 (1.2) Unknown
Intrathecal 277 (36.3 108 (1–420) —
Intravenous 236 (30.9) 10,000 (45–198,000) —
Oral 250 (32.7) Unknown —
Radiotherapy TCD (Gray) TCD (Gray)
Abdominal radiotherapy 47 (6.2) 23 (10–40) 29 (34) 21 (15–30)
Total body irradiation 26 (3.4) 10 (6–20) —
Spinal irradiation 23 (3.0) 40 (21–44) —
Nephrectomy 85 (11.3)
Renal replacement therapya 3 (0.5)
T-NHL, T cell non-Hodgkin’s lymphoma; TCD, total cumulative dose.
aRenal replacement therapy includes dialysis and renal transplantation.
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Treatment with carboplatin, cyclophosphamide, and MTX
was not significant associated with eGFR (Table 3).
Albuminuria
Albuminuria was significantly more often present in
survivors after nephrectomy (25% versus 12% if no ne-
phrectomy, P=0.01) and after abdominal radiotherapy
(39% versus 11% if no abdominal radiotherapy, P,0.001)
(Supplemental Table 1). Macroalbuminuria was rare
(n=10, 2.0%) and was present in four renal tumor survi-
vors (Table 2). After adjustment for age, sex, age at diag-
nosis, and BMI, this risk of albuminuria was significantly
higher after combination treatment with nephrectomy and
abdominal radiotherapy (OR=3.14, 95% CI=1.02; 9.69,
P=0.05) compared with no treatment with this combina-
tion treatment. Furthermore, being treated with high-dose
cisplatin (OR=5.19, 95% CI=1.21; 22.21, P=0.03) was signif-
icantly and independently associated with albuminuria,
whereas treatment with ifosfamide and/or carboplatin
was not (Table 3).
Tubular Function
Median U-b2MCR was 0.02 mg/mmol Cr and signifi-
cantly higher in patients treated with ifosfamide (0.03 ver-
sus 0.02 if no ifosfamide treatment, P=0.01) and spinal
irradiation (0.07 versus 0.02 if no spinal irradiation,
P=0.02) (Supplemental Table 1). After adjustment for
age, sex, age at diagnosis, and BMI, survivors treated
with high-dose ifosfamide (OR=6.19, 95% CI =2.45; 15.67,
P,0.001) and spinal irradiation (OR=12.40, 95% CI=2.06;
78.99, P=0.006) had a higher risk of having tubular dys-
function represented by U-b2MCR$0.04 mg/mmol Cr.
Blood Pressure
Arterial hypertension was present in 142 (23.4%) survi-
vors. In renal tumor survivors treated with nephrectomy,
22 subjects were hypertensive (31.4%). In survivors treated
with abdominal irradiation, 18 subjects were hypertensive
(43% versus 22% in survivors not treated with abdominal
irradiation, P=0.003) (Supplemental Table 1).
Discussion
In the current study among nearly 800 survivors of
childhood cancer, we investigated a broad spectrum of
parameters of chronic kidney impairment after a median
follow-up of 18 years (range=5–58 years). Nephrectomy,
abdominal irradiation, high-dose cisplatin, and high-dose
ifosfamide were found to be independent risk factors for
renal impairment, whereas former treatment with cyclo-
phosphamide or MTX was not.
High-dosed abdominal radiotherapy, total body irradi-
ation, ifosfamide, cisplatin, and carboplatin have been
described as risk factors for renal impairment in several
studies (24–27). However, in these studies, follow-up time
was relatively short, and patient numbers were small. A
recent study in a large cohort of childhood cancer survi-
vors 12 years after diagnosis described nephrectomy and
the combination of nephrectomy with abdominal radio-
therapy as risk factors for renal damage, represented by
hypertension, proteinuria, and reduced glomerular func-
tion (28). In the present study, with a median follow-up of
18 years, we showed that nephrectomy and the combina-
tion of nephrectomy with abdominal radiotherapy were
associated with a decreased glomerular function and albu-
minuria but not tubular dysfunction.
Albuminuria, however, has been described to be asso-
ciated with both glomerular and tubular dysfunction,
because it is the result of the balance between glomerular
filtration and tubular reabsorption (29,30). In case of tubu-
lar dysfunction, reabsorption of filtered albumin is de-
creased, causing albuminuria. Based on in vitro studies,
Birn and Christensen (29) hypothesized that excess albu-
min in the tubular lumen, caused by glomerular dysfunc-
tion, may lead to interstitial inflammation and fibrosis,
causing tubular damage (29,31,32). These findings illus-
trate that both glomerular and tubular dysfunction
play a role in the existence of albuminuria.
Short-term glomerular and/or tubular dysfunction after
treatment with cisplatin, carboplatin, or ifosfamide has
been thoroughly described before, although studies in-
vestigating multiple treatment effects after very long-term
follow-up are not available (24,26,33). Our data show that
Table 2. Frequency, median, and range for estimated GFR, albumin-to-creatinine ratio, and urinary b2-microglobulin creatinine ratio
Renal Function Parameters Complete Group of AdultChildhood Cancer SurvivorsN (%)
Adult Renal Tumor
Survivors N (%)
Glomerular function (estimated GFR; ml/min per 1.73 m2)
.90 501 (65.7) 34 (40.0)
60–90 241 (31.6) 44 (51.8)
30–59 16 (2.1) 4 (4.7)
15–29 2 (0.3) 0
,15 3 (0.4) 3 (3.5)
Albumin to creatinine ratio (mg/mmol Cr)
Measurements/total group 496/763 61/85
,2.5 (if man) or ,3.5 (if woman) 430 (86.7) 46 (75.4)
$2.5–25 (if man) or $2.5–25 (if woman) 56 (11.3) 11 (18.0)
.25 (if man) or .35 (if woman) 10 (2.0) 4 (6.6)
Urinary b2-microglobulin creatinine ratio (mg/mmol Cr)
Measurements/total group 478/763 59/85
,0.04 348 (73) 41 (69)
$0.04 130 (27) 18 (31)
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tubular and glomerular impairment caused by former
treatments with high-dose ifosfamide and high-dose cis-
platin is still present at very long-term follow-up.
Some studies suggested that cyclophosphamide is not
nephrotoxic in children with cancer, but up until now,
long-term follow-up studies in large cohorts that confirmed
this finding are not available. We show for the first time
that cyclophosphamide on the long term is not nephrotoxic.
The difference between the nephrotoxic effect of cyclo-
phosphamide and its isomer ifosfamide may be explained
by the differences in pharmacokinetics and pharmacody-
namics (34). A recent study using murine and human
proximal tubule cells showed that specific renal uptake
of the metabolites of ifosfamide and not cyclophospha-
mide is the basis for the differential effect in nephrotoxi-
city between ifosfamide and cyclophosphamide (35). Our
finding that ifosfamide and not cyclophosphamide is per-
sistently nephrotoxic, even after almost 20 years of follow-
up, may be useful for the ongoing discussion on the role
of ifosfamide in current treatment protocols for pediatric
sarcomas (36). However, in the design of upfront proto-
cols, not only nephrotoxicity but also other late sequelae,
such as gonadal damage, should be taken into account
(37,38).
Carboplatin is a cisplatin analog, but it is less nephro-
toxic than cisplatin. Carboplatin treatment has been re-
ported to be associated with tubular and to a lesser extent,
glomerular dysfunction. In the current study, former
treatment with carboplatin was not associated with tubular
or glomerular dysfunction. However, because the number
of survivors treated with carboplatin was relatively small
in this study, results should be interpreted with caution.
The contribution of MTX to nephrotoxicity was reported
during and shortly after treatment (5,39,40). For the first
time, we show that MTX-related acute nephrotoxicity
seems to be completely reversible, because after long-
term follow-up, MTX-treated cancer survivors did not
manifest glomerular or tubular dysfunction.
Renal tumor survivors treated with nephrectomy had a
significantly lower glomerular function than survivors who
kept both kidneys. Nephrectomy is known to result in
compensatory hypertrophy and hyperfiltration of the
remaining kidney because of loss of 50% of nephrons,
leading to glomerulosclerosis, albuminuria, and high BP
in the long run (41). A meta-analysis reported a decrease in
eGFR of 10–20 ml/min per 1.73 m2 after 5–10 years in
healthy adult renal graft donors. Moreover, 12% of healthy
donors reached an eGFR below 60 ml/min per 1.73 m2
(42,43). Furthermore, unilateral nephrectomy for several
renal diseases in childhood (including obstructive urop-
athy and reflux nephropathy) resulted in a reduced
eGFR (median=85 ml/min per 1.73 m2) after very long-
term follow-up (44). It is remarkable that, in our group
of renal tumor survivors treated with nephrectomy and
additional nephrotoxic treatment, renal function was
well maintained with a mean eGFR of 87.3 ml/min per
1.73 m2, although eGFR was significantly lower than in
the normal population (SDS=20.6). Thus, renal function
was relatively well preserved in our cohort of childhood
cancer survivors 18 years after treatment with nephrec-
tomy whether combined with abdominal irradiation or
nephrotoxic agents.
Hypertension can be both a cause as well as a compli-
cation of renal disease, and it should therefore be moni-
tored in childhood cancer survivors, because it can be a
disguised symptom. Hypertension was present in 23%,
which is relatively high compared with previous findings
of 14% and 19% among childhood survivors; this finding
could be explained by the fact that survivors were older
and follow-up time was longer in the current study
(28,45,46). This percentage was even higher (31%) in sur-
vivors treated with unilateral nephrectomy. Because renal
impairment is highly associated with an increased risk of
cardiovascular morbidity and death, renal tumor survi-
vors should, therefore, be monitored with extra care (12).
Based on our results, we recommend intensive renal
screening (one time per 3 years) in high-risk groups (being
treated with high-dose cisplatin [.450 mg/m2] or high-
dose ifosfamide [.16,000 mg/m2] and nephrectomy with
or without abdominal irradiation) by measurement of cre-
atinine, eGFR, and albuminuria. Furthermore, treatment
with angiotensin-converting enzyme inhibition is indi-
cated not only for hypertension but also in case of isolated
microalbuminuria, because it is described to reduce car-
diovascular risk in nondiabetic patients (47).
Our study comprises nearly 90% of all adult survivors
treated and diagnosed at the Erasmus Medical Center
between 1964 and 2005, with a long and nearly complete
follow-up. A limitation of this study is the fact that urine
measurements were not part of the follow-up scheme of the
late-effects clinic before 2006. Because the reason for
selection was based on timing of follow-up rather than
patients or treatment characteristics, the chance of selection
bias is small, although it is not completely excluded.
In conclusion, lower eGFR in the long run is associated
with former treatment with unilateral nephrectomy
whether combined with abdominal irradiation, cisplatin,
or ifosfamide. Albuminuria is related to combination
treatment of nephrectomy and abdominal radiotherapy.
Persisting tubular damage is particularly associated with
treatment with ifosfamide. Treatment with cyclophospha-
mide and MTX is not related to very long-term nephrotoxic
sequelae in childhood cancer survivors.
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